Related Experiment Video
Updated: Jun 27, 2026
Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
14-3-3sigma expression and prognostic value in patients with epithelial ovarian carcinoma: a high throughput tissue
P Mhawech-Fauceglia1, F R Herrmann, C Andrews
1Department of Pathology and Laboratory Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. pmhawech1@yahoo.com
Aims:
14-3-3sigma is a potential tumor suppressor gene that when it is silenced by CpG methylation can contribute to cancer development. Previously, we showed that hypermethylation of 14-3-3sigma in human ovarian cancer and ovarian cancer cell lines, and that 14-3-3sigma hypermethylation correlated with loss of its expression by immunohistochemistry. In the present study, our aim is to determine the value of 14-3-3sigma in predicting disease outcome in series of patients with epithelial ovarian cancer.
Materials And Methods:
A tumor microarray (TMA) of 192 patients with a very detailed characteristic and follow-up was performed. The slides were immunostained with 14-3-3sigma antibody and its expression was correlated with age, tumor types, grade, stage, volume of residual tumor, response to therapy, overall survival (OS) and disease-free survival (DFS).
Results:
A marginal association with the volume of residual tumor after surgery (chi2 p = 0.044, Fischer's exact 0.051) was seen. There was no association between loss of 14-3-3sigma expression and any of age, stage, grade, tumor subtypes, and clinical response to therapy. Survival analysis according to Kaplan-Meier method showed that loss of 14-3-3sigma expression was not associated with OS or DFS (p = 0.702, p = 0.118, respectively).
Conclusion:
Even though 14-3-3sigma is involved in ovarian tumorigenesis, it does not have a prognostic value as a biomarker to predict patients' outcome.
